Emergent signs $174 million deal to make AstraZeneca’s potential COVID-19 vaccine

(Reuters) – Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker’s COVID-19 vaccine candidate.

AstraZeneca in June picked Emergent to help produce the 300 million doses of its potential COVID-19 vaccine pledged to the United States.

(Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)